27 April 2008

Sunday Herald Sun - Stem Cell Hope for Fixing Injured Knees

A WORLD-FIRST trial to be conducted in Melbourne could revolutionise the treatment of chronic knee injuries using adult stem cells.

Up to 60 Victorians are to trial a simple injection scientists believe could replace drugs - and even surgery- in treating debilitating osteoarthritis.

It could also prolong the careers of athletes, including AFL players, regularly sidelined by common cartilage tears.

Melbourne-based biotechnology company Mesoblast recently completed successful animal trials of the hi-tech procedure and believe there is a "billion-dollar market" for their technique.

The Australian trials found the injection of adult stem cells - taken from human donors' bone marrow, abdominal fat, hip, skin or teeth - protected damaged knee cartilage for up to nine months.

Professor Silviu Itescu, Mesoblast's director and chief scientific adviser, said the injected stem cells bound themselves to the cartilage, halting its degen eration.

"Is it that the cells are protecting the cartilage, or is it accelerating the rate of repair? At the moment, we don't know," he said. "Either way, the result is more cartilage, thicker cartilage."

Leading sports physician Dr Peter Larkins said stem cell therapy had the potential to prolong athletes' careers. "In terms of medical break throughs, it's a sensational prospect, if it works," he said.

The human trials, to be conducted in Melbourne and in the US, will involve about 80 pa tients aged 45-55 who have had knee arthroscopes in the pre vious month.

That is the surgery track star Jana Rawlinson famously underwent to compete in the 2004 Athens Olympics. Dr Peter Ghosh, Mesoblast's chief cartilage scientist, said the weeks after arthroscopic surgery - which typically involves the removal of a cartilage called meniscus - was the ideal time to test the injection of cells.

"As you get older, (meniscus) degenerates but, more commonly in younger people, it is also torn. It is a very common injury for football and netball players," he said.

"When it's torn, it can lock the joint and give you pain and symptoms and the joint blows up. It has to be removed."

However Dr Ghosh said the surgery, known as a meniscectomy, often fast-tracks the development of osteoarthritis, the degeneration of joint cartilage that affects about 1.3 million Australians.

"So football players and men and women in the street who have had this operation live in fear that when they reach 50 or 60, they'll be faced with this debilitating disorder."

If the trials are successful, Dr Ghosh said the "off-the-shelf' product would be on the market by 2012 and could treat "any joint that can be injected".

 

 

>>back to What They Say

 

 

Last Share Price

14 February 2011 – Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection

9 February 2011 – Chairman’s Address, CEO Presentation to EGM

31 January 2011 – Mesoblast Reports Strong Cash Position; Appendix 4C Quarterly Cash Flow Report

12 January 2011 Mesoblast – Cephalon Alliance Highlighted at JP Morgan Healthcare Conference

10 January 2011 - Interim Results from Mesoblast’s Phase 2 Heart Failure Trial Shows “Off-the-Shelf” Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization

23 December 2010 – Mesoblast Completes Acquisition of Angioblast

8 December 2010 – Mesoblast and Cephalon Enter into Strategic Alliance to Commercialize Novel Therapeutic Products for Regenerative Medicine

29 November 2010 – Building a solid futurec

19 November 2010 – Mesoblast Clear to Proceed with Angioblast Acquisition

16 November 2010 – Positive Results of Novel Heart Attack Treatment Presented at Premier USA Cardiology Conference

8 November 2010 - U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products

29 October 2010 - Notice of AGM

29 October 2010 - Mesoblast Annual Report 2010

21 October 2010 – Positive Results from Phase 2 Lumbar Fusion Trial Presented at International Investor Conference

20 October 2010 - Mesoblast Acquisition of US Company Approved by Angioblast Stockholders

14 October 2010 – Mesoblast targets broader cancer indications for bone marrow transplant product

23 September 2010 – Boardroom radio interview with CEO Silviu Itescu

22 September 2010 - Acquisition of US Company Ratified by Mesoblast Shareholders

22 September 2010: Results of Extraordinary General Meeting

22 September 2010 – Chairman Speech & CEO Presentation to EGM

20 September 2010 – Mesoblast Featured at International Scientific Conferences

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

30 November 2010 - Nomura Research; Mining the Marrow

22 November 2010 - Nomura Research: Mesoblast [MSB AU] - BUY: Trial Results Continue to Impress

16 November 2010 - Nomura Research: Mesoblast Buy: Releases Positive Clinical Trial Data in Heart Disease; NPV $19

8 October 2010 – Nomura Research: Updating forecasts for Angioblast

10 September 2010 - Southern Cross Equities Note to Clients : Mesoblast No. 1 Biotech Recommendation

10 September 2010 - Bioshares Analysis: Mesoblast Continues to Open New Product Opportunities

26 August 2010 - Nomura Global Equities Research: FY 2010 Making Their Bones

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

6 July 2010 - Nomura Global Equities Research: A Biotech Platform Technology; Anchor Report

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine